Balamuth Naomi J, Nichols Kim E, Paessler Michele, Teachey David T
Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
J Pediatr Hematol Oncol. 2007 Aug;29(8):569-73. doi: 10.1097/MPH.0b013e3180f61be3.
Hemophagocytic lymphohistiocytosis is a rare, life-threatening complication of Epstein Barr virus (EBV) infection. Current treatments are directed at reducing virus-induced immune dysregulation. Addition of agents that eliminate EBV-infected B cells may improve therapeutic efficacy. On the basis of the observations that the anti-CD-20 monoclonal antibody rituximab reduces disease burden in individuals with EBV-associated lymphoproliferative disorders, we treated a patient with severe EBV-hemophagocytic lymphohistiocytosis using a combination of rituximab and chemotherapy. This patient demonstrated a rapid clinical response and an 18-fold reduction in EBV viral load within 24 hours of receiving rituximab. He remains free of disease 8 months after completing treatment.
噬血细胞性淋巴组织细胞增生症是一种由爱泼斯坦-巴尔病毒（EBV）感染引起的罕见且危及生命的并发症。目前的治疗旨在减少病毒诱导的免疫失调。添加能清除EBV感染的B细胞的药物可能会提高治疗效果。基于抗CD20单克隆抗体利妥昔单抗可减轻EBV相关淋巴增殖性疾病患者疾病负担的观察结果，我们使用利妥昔单抗和化疗联合治疗了一名患有严重EBV噬血细胞性淋巴组织细胞增生症的患者。该患者在接受利妥昔单抗治疗后24小时内临床反应迅速，EBV病毒载量降低了18倍。完成治疗8个月后，他仍未发病。
